Unlock the full potential of your molecule
At Inoviem Scientific, we share your goal: to fight diseases and address unmet medical needs. We support every stage of drug development—from target validation to clinical trials—using human pathological tissues and our established platforms working directly on patient tissues. Whether you’re developing small molecules or biologics for cancer, autoimmune, metabolic, or other diseases, we provide enabling information to unlock the full potential of your molecule with faster breakthroughs, lower risks, and a competitive edge.
Our established platforms use real human tissue data to reveal how your drug will perform in the organism, helping you validate targets, understand mechanisms of action, and identify predictive biomarkers—saving you time, money, and resources.
https://www.youtube.com/watch?v=qK0T7NI5kk0&t=1s
Accelerating and securing the drug development process
Traditional drug development models often fail to predict how a treatment will perform in humans. We change that by working directly with human tissues, providing results that reflect the real-world human response. This real patient-centric approach allows us to:
- Increased relevance: We use patient-derived materials directly reflecting the human response to potential drugs, providing a more accurate picture of efficacy and safety compared to traditional models. This real-world data helps you flag ineffective treatments sooner, saving valuable time and resources.
- De-risking your pipeline: We understand drug mechanisms through patient-derived materials allows for early identification of potential issues, saving resources and reducing the risk of costly late-stage failures.
- Improve clinical trial design: By incorporing predictive biomarkers and patient stratification, we help you select the right cohort of responder patients, improving trial success rates and reducing wasted efforts.
What our clients say
The Inoviem technology has a great potential as a target ID platform. Service itself was fantastic. Impressed with Inoviem’s rigor in performing the experiments, analyzing the data and creating the report, and their overall depth of scientific knowledge.
Brahama GoshPrincipal Scientist, Oncology & Discovery Chemistry at Johnson & Johnson
We were very satisfied by the huge amount of information that can be released by an NPOT analysis. We had very valuable interactions and trust.
Marcello TrevisanHead of Target Discovery at CHIESI Faramaceutici
We are very satisfied with the work performed in collaboration with Inoviem. The NPOT technology is really original and brings valuable information for target validation, completed by SPR.
Arianne ScoumanneSenior Scientist Preclinical R&D at ITEOS
Previous
Next
How we bridge the gap between pre-clinical and clinical success
Our approach is based on the simple idea that current technologies fail to consider the natural environment in which a drug will have its beneficial effect. Due to concerns about the drug-target mode of action, the target is usually removed from its natural environment, resulting in the loss of important information and biasing the drug development process. The consequences of this are commercialized drugs with unexpected undesired effects or a loss of therapeutic efficacy.
Inoviem avoids this shortcoming by developing label-free technologies working directly on human tissue and using human samples as the analysis substrate; technology and physiology are therefore reconciled.
Ongoing investment in developing complementary technologies ensures that we remain at the forefront of innovation and bring the most creative and effective translational solutions to our clients.
News, events & resources
See more resources
